Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
The Opportunity
RevMed is seeking an experienced, collaborative Senior Director, Global SOX to lead and scale the Company’s Sarbanes-Oxley compliance and internal controls program. This role has enterprise-wide governance responsibility for ICFR, ITGCs, ITACs, automated controls, key reports, and controls supporting evolving business processes, systems, commercial readiness, and global expansion.
As a key Controllership leader, this role partners with functions, auditors, and process owners across the United States, Europe, Japan, Canada, and other markets. The leader will establish global SOX governance and practical regional execution, ensuring rigorous compliance while building risk-based, scalable controls that work effectively with business operations.
This role reports to the VP, Finance, Controller, is based at RevMed’s Redwood City headquarters, and works closely with regional Finance, IT, and business teams.
Responsibilities
Global SOX Program Leadership
ITGC, Systems and Commercial Readiness
Auditor Coordination, Remediation and Team Leadership
Required Skills, Experience and Education:
Bachelor’s degree or higher in Accounting, Finance, Information Systems, Business Administration, or a related field.
CPA, CIA, CISA, or equivalent certification strongly preferred; at least one relevant certification expected.
12+ years of progressive experience in SOX, internal controls, IT audit, public accounting, internal audit, controllership, or related fields.
Significant experience leading a SOX 404 program for a publicly traded, multi-entity company with international operations.
Deep knowledge of SOX 404, COSO, PCAOB auditing standards, SEC reporting requirements, ICFR, management review controls, and financial reporting risk assessment.
Strong ITGC and ITAC experience across access, change management, SDLC, computer operations, interfaces, automated controls, key reports, SOC report review, CUECs, and third-party provider controls.
Experience supporting global ERP or financial system implementations, upgrades, integrations, or transformations.
Strong understanding of close, consolidation, intercompany, foreign currency, SEC reporting, equity, payroll, procurement, AP, treasury, leases, revenue, inventory, and other significant accounting processes.
Proven ability to influence cross-functional and cross-cultural stakeholders, drive accountability, and communicate clearly with senior leaders, auditors, control owners, and technical and non-technical audiences.
Preferred Skills:
Experience in a global biotech, pharmaceutical, life sciences, or healthcare company preparing for or operating in a commercial-stage environment.
Experience with multi-country launch readiness, revenue recognition, gross-to-net, inventory, third-party logistics, government pricing, specialty distributors / pharmacies, or patient support programs.
Experience with NetSuite, Coupa, Workday, ADP, equity platforms, Active Disclosure / Workiva, lease and commercial systems, GRC / SOX tools, data warehouses, and reporting platforms.
Experience building or scaling an in-house global SOX function, including centralized standards and regional execution.
Experience implementing SOX automation, evidence workflows, dashboards, analytics, or AI-enabled monitoring.
Public accounting or Big 4 / national firm experience strongly preferred.
#LI-GL1 #LI-Hybrid
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to careers@revmed.com so we can share these impersonations with our IT team for tracking and awareness.

We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.